Antoine Yver - 27 May 2021 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Medical Officer
Signature
/s/ Marella Thorell, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
27 May 2021
Net transactions value
$0
Form type
4
Filing time
01 Jun 2021, 20:48:58 UTC
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Award $0 +833,897 $0.000000 833,897 27 May 2021 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F3 The shares are subject to a right of repurchase by the Issuer, which vest as follows: 25% of the shares will vest on May 17, 2022 and the remaining 75% of the shares will vest in 36 monthly installments on the first day of each month thereafter.